Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 10/20 | 0.38 |
| ▸ | ADH1C | P00326 | 8/20 | 0.38 |
| ▸ | ADH1B | P00325 | 4/20 | 0.38 |
| ▸ | ADH7 | P40394 | 3/20 | 0.38 |
| ▸ | ADH4 | P08319 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16256831 | 1.00 | ADH1A (0.38) | ADH1AADH1CADH1BADH7ADH4 | |
| SCHEMBL918192 | 1.00 | ADH1A (0.38) | ADH1AADH1CADH1BADH7ADH4 | |
| SCHEMBL16256833 | 1.00 | ADH1A (0.38) | ADH1AADH1CADH1BADH7ADH4 | |
| SCHEMBL918190 | 1.00 | ADH1A (0.38) | ADH1AADH1CADH1BADH7ADH4 | |
| SCHEMBL24695998 | 0.96 | ADH1A (0.41) | ADH1AADH1CADH1BADH7ADH4 | |
| SCHEMBL16181452 | 0.96 | ADH1A (0.41) | ADH1AADH1CADH1BADH7ADH4 | |
| SCHEMBL4405026 | 0.96 | ADH1A (0.41) | ADH1AADH1CADH1BADH7ADH4 | |
| SCHEMBL9883858 | 0.92 | — | — | |
| SCHEMBL14639642 | 0.85 | ADH1A (0.31) | ADH1AADH1CADH1BADH7 | |
| SCHEMBL14639774 | 0.85 | ADH1A (0.31) | ADH1AADH1CADH1BADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024169871-A1 | BTK INHIBITOR AND USE THEREOF | 江苏威凯尔医药科技有限公司 | 2024-08-22 | — | — | WO | disclosed |
| CN-118515673-A | BTK inhibitor and application thereof | 江苏威凯尔医药科技有限公司 | 2024-08-20 | — | — | CN | disclosed |
| WO-2024141052-A1 | ESTROGEN-RECEPTOR MODULATOR AND USE THEREOF | 江苏威凯尔医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-118271284-A | Estrogen receptor modulators and uses thereof | 江苏威凯尔医药科技有限公司 | 2024-07-02 | — | — | CN | disclosed |
| WO-2020034476-A1 | POROUS ORGANIC CAGE LIGAND CONTAINING P AND N AND COMPLEX CATALYST AND APPLICATION | 中国科学院大连化学物理研究所 | 2020-02-20 | — | — | WO | disclosed |
| WO-2020034477-A1 | POROUS ORGANIC CAGE LIGAND CONTAINING P AND N, PREPARATION THEREFOR AND USE THEREOF | 中国科学院大连化学物理研究所 | 2020-02-20 | — | — | WO | disclosed |
| EP-2703378-B1 | POLYPHENOLIC COMPOUNDS AND EPOXY RESINS COMPRISING CYCLOALIPHATIC MOIETIES AND PROCESS FOR THE PRODUCTION THEREOF | BLUE CUBE IP LLC (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2534189-B1 | PHOSPHORUS-CONTAINING EPOXY RESIN | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-05-06 | — | — | EP | disclosed |
| US-8729181-B2 | Aromatic polycyanate compounds and process for the production thereof | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-05-20 | — | — | US | disclosed |
| EP-2703378-A1 | Polyphenolic compounds and epoxy resins comprising cycloaliphatic moieties and process for the production thereof | Dow Global Technologies LLC (US) | 2014-03-05 | — | — | EP | disclosed |
| WO-2011100049-A2 | PHOSPHORUS-CONTAINING EPOXY RESIN | DOW GLOBAL TECHNOLOGIES LLC (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110098380-A1 | POLYPHENOLIC COMPOUNDS AND EPOXY RESINS COMPRISING CYCLOALIPHATIC MOIETIES AND PROCESS FOR THE PRODUCTION THEREOF | DOW GLOBAL TECHNOLOGIES INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110009562-A1 | AROMATIC POLYCYANATE COMPOUNDS AND PROCESS FOR THE PRODUCTION THEREOF | DOW GLOBAL TECHNOLOGIES INC. (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2254928-A1 | AROMATIC POLYCYANATE COMPOUNDS AND PROCESS FOR THE PRODUCTION THEREOF | Dow Global Technologies Inc. (US) | 2010-12-01 | — | — | EP | disclosed |
| EP-2254853-A1 | POLYPHENOLIC COMPOUNDS AND EPOXY RESINS COMPRISING CYCLOALIPHATIC MOIETIES AND PROCESS FOR THE PRODUCTION THEREOF | Dow Global Technologies Inc. (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20090325889-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | CAMPBELL DAVID ALAN | 2009-12-31 | — | — | US | disclosed |
| WO-2009114469-A1 | AROMATIC POLYCYANATE COMPOUNDS AND PROCESS FOR THE PRODUCTION THEREOF | DOW GLOBAL TECHNOLOGIES INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009114383-A1 | POLYPHENOLIC COMPOUNDS AND EPOXY RESINS COMPRISING CYCLOALIPHATIC MOIETIES AND PROCESS FOR THE PRODUCTION THEREOF | DOW GLOBAL TECHNOLOGIES INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| EP-0172427-B1 | PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER | Shin-Etsu Chemical Co., Ltd. (JP) | 1989-07-05 | — | — | EP | disclosed |
| EP-0172427-A2 | Process for production of vinyl chloride polymer | Shin-Etsu Chemical Co., Ltd. (JP) | 1986-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009562-A1 | AROMATIC POLYCYANATE COMPOUNDS AND PROCESS FOR THE PRODUCTION THEREOF | PAH, TYR, ARNT | ADH1A 3226/4885ADH1C 3033/4885ADH1B 1408/4885 |
| US-20090325889-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PREP, HPN, PRSS1 | ADH1A 1996/4885ADH1C 1322/4885ADH1B 469/4885 |
| US-20110098380-A1 | POLYPHENOLIC COMPOUNDS AND EPOXY RESINS COMPRISING CYCLOALIPHATIC MOIETIES AND PROCESS FOR THE PRODUCTION THEREOF | CRH, CRHBP, COMT | ADH1A 923/4885ADH1C 635/4885ADH1B 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.